Validating LLMs for GxP work — scope, evidence, and exactly what an auditor will ask

If your first instinct is "we'll let the LLM draft it, and a human will check", pause. That arrangement can be compliant — but only if you validate the tool, define the boundaries, and keep evidence an auditor can follow.

I've been through three tool validations and one surprised auditor visit in the last 18 months. To be fair, regulators expect a risk‑based approach: GxP obligations don't disappear because the function lives inside a large language model. Below is the practical checklist I use when deciding scope, assembling evidence, and answering an auditor's questions.

What counts as GxP-relevant work with an LLM?

Start by drawing a clear line. In practice this means classifying tasks by whether the output can affect patient safety, product quality, trial data, or regulated records.

Examples that are almost always GxP-relevant:

• Summaries of clinical data or adverse event narratives that feed safety decisions.
• Drafting or proposing CAPA root causes, corrective actions or investigation reports.
• Generating release decisions, batch record annotations, or deviations investigation text.
• Triage that influences regulatory reporting or clinical follow-up.

Lower-risk tasks (administrative drafting, non‑regulated marketing copy) still need controls, but can sit outside the validated perimeter.

Define scope and acceptance criteria up front

Validation starts with requirements. I write a pragmatic User Requirements Specification (URS) that contains:

• The exact tasks the LLM will perform.
• Expected inputs and outputs (format, fields, permitted edits).
• Acceptance criteria (e.g. sensitivity/specificity for triage; maximum acceptable hallucination/error rate).
• Human oversight rules: who reviews, how many reviewers, and what "final sign‑off" means.

Use a risk-based tag (low/medium/high) for each function and link it to your risk-management record (ISO 14971 or your company equivalent). If the LLM influences device risk control, document that linkage.

The evidence auditors will want — and how to present it

Auditors ask for traceability and reproducibility. Prepare a tidy, linked evidence package — not a pile of screenshots.

Essential artefacts:

• URS and functional specification (what the tool must do).
• Validation plan and protocol showing test cases and pass/fail criteria.
• Test cases and results (include edge cases and failure modes).
• Model provenance: vendor/model name, version, deployment date, update history.
• Training‑data provenance summary if available — at minimum, vendor attestations about data sources and data handling.
• Configuration records: prompt templates, system settings, filters, and any post‑processing.
• Access control and audit‑trail records (21 CFR Part 11 considerations if applicable).
• SOPs for use, review, and escalation (who reviews outputs; when to refuse).
• Monitoring logs and performance metrics (examples below).
• Change control records and a plan for re‑validation upon model updates.

A traceability matrix linking URS → tests → results makes an auditor's life easier.

What auditors will actually ask (and how I answer)

Expect these specific lines of questioning. My answers are concise, evidence-first.

• "How did you classify this tool's risk?" — Show your risk assessment entry tied to product/process risk and ISO 14971.
• "Show us the URS and protocol." — Present versioned documents with review/approval signatures.
• "How do you detect and handle hallucinations or incorrect outputs?" — Provide test cases where the model failed, show mitigation (mandatory human review; reject rates), and link any resulting CAPA.
• "What change control if the vendor updates the model?" — Show your vendor change agreement, automatic notification mechanism, and re‑validation trigger points.
• "Who has access and what audit trail exists?" — Demonstrate role-based access, logs, and how outputs are captured in the QMS (document control).
• "How do you preserve data integrity and confidentiality?" — Show data flow diagrams, pseudonymisation measures, and GDPR alignment where personal data are possible.
• "Can you reproduce a decision?" — Provide saved prompts, inputs, model version and output archive for sample cases.

Monitoring and post‑deployment control

Validation isn't a one‑time tick box. You need continuous performance monitoring:

• Key performance indicators: accuracy, false positive/negative rates, reviewer override rate, time‑to‑review.
• Thresholds and frequency: daily sampling for high-risk outputs; weekly or monthly for lower risk.
• Incident handling: log, investigate, and CAPA for unexpected trends (this is where automated CAPAs or AI-guided CAPA assistance can help triage).
• Re‑validation triggers: vendor model change, prompt template change, drift in performance metrics.

Log everything into the QMS so you have connected workflow and traceability from output → review → CAPA → corrective action.

Practical tips that saved me time

• Treat LLMs as "software as a medical device" when they influence patient or product decisions; apply your existing software-validation templates.
• Keep prompt templates controlled; the exact prompt is part of your configuration.
• Archive representative inputs/outputs as part of your evidence set — periodic snapshots are far more persuasive than live demos.
• Use a short, user‑facing SOP that tells reviewers precisely what to look for (reviewability matters).
• If you integrate the LLM with your eQMS, ensure the integration preserves audit trails and document linking. Find evidence instantly — auditors dislike a forensic investigation.

Final thought

Auditors want to see that you understand the risks and have reproducible controls. To be fair, that is largely the same ask as for any other computerised system — except LLMs add provenance and hallucination controls to the checklist.

What GxP task did you classify as high risk for an LLM, and how did you demonstrate its validation to your auditor?